SETD2属于组蛋白甲基转移酶蛋白家族,并与具有不同临床和分子特征的三个在病理学上不同的实体相关:Luscan-Lumish综合征(LLS),智力发育障碍,常染色体显性70(MRD70),和Rabin-Pappas综合征(RAPAS)。LLS[MIM#616831]是一种过度生长障碍,包括智力障碍,说话延迟,自闭症谱系障碍(ASD),大头畸形,身材高大,和电机延迟。RAPAS[MIM#6201551]是一种最近报道的多系统疾病,其特征是全球和智力发育严重受损。低张力,喂养困难,未能茁壮成长,小头畸形,和畸形的面部特征。其他神经系统发现可能包括癫痫发作,听力损失,眼科缺陷,和大脑成像异常。其他器官系统的参与是可变的,包括骨骼,泌尿生殖系统,心脏,和潜在的内分泌。据报道,在SETD2中携带错义变异p.Arg1740Gln的三名患者患有中度智力障碍,言语困难,和行为异常。更多的变量发现包括张力减退和异形特征。由于与前两种表型的差异,这个协会后来被命名为智力发育障碍,常染色体显性70[MIM620157]。这三种疾病似乎是等位基因,是由功能丧失引起的,函数增益,或SETD2基因中的错义变体。在这里,我们描述了18例SETD2变异的新患者,其中大多数具有LLS表型,并回顾了先前在科学文献中报道的33例SETD2变异患者。本文提供了LLS患者的报告数量的扩展,并强调了与SETD2相关的三种表型之间的临床特征以及相似性和差异。
SETD2 belongs to the family of histone methyltransferase proteins and has been associated with three nosologically distinct entities with different clinical and molecular features: Luscan-Lumish syndrome (LLS), intellectual developmental disorder, autosomal dominant 70 (MRD70), and Rabin-Pappas syndrome (RAPAS). LLS [MIM #616831] is an overgrowth disorder with multisystem involvement including intellectual disability, speech delay, autism spectrum disorder (ASD), macrocephaly, tall stature, and motor delay. RAPAS [MIM #6201551] is a recently reported multisystemic disorder characterized by severely impaired global and intellectual development, hypotonia, feeding difficulties with failure to thrive, microcephaly, and dysmorphic facial features. Other neurologic findings may include seizures, hearing loss, ophthalmologic defects, and brain imaging abnormalities. There is variable involvement of other organ systems, including skeletal, genitourinary, cardiac, and potentially endocrine. Three patients who carried the missense variant p.Arg1740Gln in SETD2 were reported with a moderately impaired intellectual disability, speech difficulties, and behavioral abnormalities. More variable findings included hypotonia and dysmorphic features. Due to the differences with the two previous phenotypes, this association was then named intellectual developmental disorder, autosomal dominant 70 [MIM 620157]. These three disorders seem to be allelic and are caused either by loss-of-function, gain-of-function, or missense variants in the SETD2 gene. Here we describe 18 new patients with variants in SETD2, most of them with the LLS phenotype, and reviewed 33 additional patients with variants in SETD2 that have been previously reported in the scientific literature. This article offers an expansion of the number of reported individuals with LLS and highlights the clinical features and the similarities and differences among the three phenotypes associated with SETD2.